Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab SC vs IV in Adjuvant Melanoma
NCT05297565Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2022
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of nivolumab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Adverse Events, Number of Participants With Serious Adverse Events and 2 more. Started Aug 2022; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05297565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05297565.